Kelsee, well we've got 3  weeks until the end of Q1. The Rvx (and Zenith?) bank accounts must be running down. In addition, if the SSA recommends a larger sample then it will not just be the funding required to complete BoM as it is but also the funding to finance the larger sample based on the SSA.

With a cash burn rate of $3.3 million per month and if they are close to $zero in the next few months in the bank (unknown) you can do a rough estimate as to what's required to get to the end of 2018 even without the additional trials.

So I am hoping we will see an announcement of a strong strategic partner soon. With all of the strong science and continuing good news like the 6th positive DSMB report it is hard to imaging that large investors or BPs are not jumping in.

To me the fact that ABBVie has developed their own BD-2 selective molecule, ABBV-744, on their own it may suggests BPs have options to go it alone? It also lends credibility to apabetalone i.e. the big boys are taking action on selective BET inhibitors (momentum continues to grow).

The fact that ABBV-744 is going to be trialed on mCRPC raises the possibility that apabetalone may have applications in cancers as BDAZ pointed out.

I've got my fingers crossed for big $ action by RVX soon.

Toinv